Organon & Co. CEO Kevin Ali is the first to admit that the company faced a lot of skepticism when it spun out of Merck & Co., Inc. with three seemingly disparate sets of assets – established products, biosimilars and women’s health – with plans to most aggressively invest in women’s health for growth. Ali is also the first to note that the company has delivered on its promises across all three areas during its first year.
“Investors and analysts at the very beginning when we first spun out were wondering how these three pieces of the business fit together,” he said in an interview with Scrip. They had questions about whether the established brands business was sustainable through upcoming patent expiries and with 95% of that revenue coming from outside the US
“We're really excited that in the first year … we've been able to check the
